Cisplatin/Etoposide or Paclitaxel/Carboplatin with Concurrent Radiation Therapy in Stage IIIB Non-Small Cell Lung Cancer: A One-Year Randomized Trial at a Low-Resource Setting - Shuayb CCRT Trial

Oncology & Radiotherapy Centre, Square Hospitals Ltd.0 个研究点目标入组 60 人开始时间: 2017年7月20日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Inclusion criteria included Non-small cell lung cancer proved by pathology or cytology; inoperable AJCC stage IIIB prior to the initiation of treatment; age: 18 to 75; Eastern Cooperative Oncology Group (ECOG) performance status =2; lose of weight <10% during 6 months; biochemical tests values: WBC =3.5×109/L, neutrophils =1.5×109/L, platelets =100×109/L, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin =1.5 × the upper limit of the institutional normal range; creatinine concentration =120 umol/L, and creatinine clearance=50 ml/min; no serious diseases of important organs; written informed consent signed prior to enrollment.

•Exclusion Criteria included pretreatment with radiotherapy, chemotherapy or biological agents; pregnant or lactating woman; serious diseases (include significant cardiovascular disease or uncontrolled diabetes) of important organs; other malignancies; active uncontrolled infection; joined in other clinical trial.

发起方

Oncology & Radiotherapy Centre, Square Hospitals Ltd.